Description

BRILINTA 60MG (1X14)

Indications

BRILINTA (ticagrelor) 60mg is indicated for the prevention of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS), including those who have experienced a heart attack or unstable angina. It is also indicated for patients who have undergone percutaneous coronary intervention (PCI) to reduce the risk of stent thrombosis. This medication is prescribed to patients to improve outcomes following a cardiac event and to prevent future occurrences.

Mechanism of Action

BRILINTA is an oral antiplatelet agent that works by inhibiting the P2Y12 receptor on platelets. Ticagrelor is a reversible inhibitor of this receptor, which plays a crucial role in platelet activation and aggregation. By blocking the P2Y12 receptor, BRILINTA reduces the ability of platelets to clump together, thereby decreasing the formation of blood clots. This mechanism is essential in preventing thrombotic events in patients with a history of cardiovascular issues.

Pharmacological Properties

BRILINTA is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 to 3 hours. The bioavailability of ticagrelor is approximately 36%, and it undergoes extensive hepatic metabolism, primarily via the cytochrome P450 enzyme system, particularly CYP3A4 and CYP3A5. The elimination half-life of ticagrelor is approximately 7 hours, with its active metabolite having a longer half-life. The drug is primarily excreted via the feces, with a small percentage eliminated through urine.

Contraindications

BRILINTA is contraindicated in patients with a history of hypersensitivity to ticagrelor or any of its components. It should not be used in patients with active bleeding, such as peptic ulcer disease or intracranial hemorrhage. Additionally, it is contraindicated in patients with severe hepatic impairment and those who are concomitantly using strong CYP3A4 inhibitors, as these can significantly increase ticagrelor levels and the risk of bleeding.

Side Effects

Common side effects of BRILINTA include bleeding complications, which may manifest as easy bruising, prolonged bleeding from cuts, or more serious internal bleeding. Other side effects may include dyspnea, headache, dizziness, and gastrointestinal disturbances such as nausea and diarrhea. Rare but serious adverse effects include severe allergic reactions, liver enzyme elevations, and thrombotic thrombocytopenic purpura (TTP). It is essential for patients to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended initial dose of BRILINTA is 180 mg, followed by a maintenance dose of 90 mg twice daily for the first year after an acute coronary syndrome event. After one year, the maintenance dose may be reduced to 60 mg twice daily based on the clinical judgment of the healthcare provider and the patient’s risk factors. BRILINTA should be taken with or without food, and patients should be advised to swallow the tablets whole, without crushing or chewing them, to ensure proper absorption.

Interactions

BRILINTA has several important drug interactions that can affect its efficacy and safety. Strong CYP3A4 inhibitors, such as ketoconazole, clarithromycin, and ritonavir, can increase the plasma concentration of ticagrelor, leading to a higher risk of bleeding. Conversely, strong CYP3A4 inducers, such as rifampin, can decrease ticagrelor levels, reducing its effectiveness. Patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Prior to initiating therapy with BRILINTA, a thorough medical history should be obtained, and patients should be assessed for risk factors for bleeding. Caution is advised in patients with a history of bleeding disorders, recent surgery, or those who are at increased risk of falls. Regular monitoring of liver function tests is recommended, especially in patients with pre-existing liver conditions. Patients should also be counseled about the signs and symptoms of bleeding and advised to seek immediate medical attention if they experience any severe or unusual bleeding.

Clinical Studies

BRILINTA has been evaluated in several clinical trials, demonstrating its efficacy in reducing cardiovascular events. The PLATO (Platelet Inhibition and Patient Outcomes) trial was a pivotal study that compared BRILINTA to clopidogrel in patients with ACS. The results showed that BRILINTA significantly reduced the risk of major cardiovascular events, including cardiovascular death, myocardial infarction, and stroke, compared to clopidogrel. Additionally, the study highlighted the drug’s rapid onset of action and its favorable safety profile, particularly concerning stent thrombosis rates.

Conclusion

BRILINTA 60mg is a critical therapeutic option for patients at high risk of thrombotic cardiovascular events, particularly those with acute coronary syndrome. Its unique mechanism of action as a reversible P2Y12 inhibitor provides significant benefits in preventing platelet aggregation and subsequent clot formation. While the medication is generally well-tolerated, awareness of potential side effects, contraindications, and drug interactions is essential for safe and effective use. Ongoing clinical studies continue to support the role of BRILINTA in improving patient outcomes in cardiovascular care.